Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,252
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12618082 | Engineered muscle targeting compositions | 🖼🧊📄§ | 2026-05-05 | 2042-03-29 | 0 | 31 |
| 12617791 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | 🖼🧊📄§ | 2026-05-05 | 2041-10-15 | 0 | 31 |
| 12617792 | Purine derivative, intermediate and application thereof in preparing anticancer medicine | 🖼🧊📄§ | 2026-05-05 | 2040-10-21 | 0 | 31 |
| 12617757 | Compounds and modules for inhibition of pre-miR-21 and their use in treatment of certain cancers | 🖼🧊📄§ | 2026-05-05 | 2040-10-29 | 0 | 31 |
| 12617759 | Modifier of four-membered ring derivative, preparation method and application thereof | 🖼🧊📄§ | 2026-05-05 | 2040-10-29 | 0 | 31 |
| 12617762 | Carboxy derivatives with antiinflamatory properties | 🖼🧊📄§ | 2026-05-05 | 2040-12-23 | 0 | 31 |
| 12617790 | Mitragynine analogs and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12617805 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-19 | 0 | 31 |
| 12617811 | HPK1 inhibitors and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-02 | 0 | 31 |
| 12617812 | Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-25 | 0 | 31 |
| 12617807 | Long lasting opioid reversal using hydrogen peroxide-induced release in blood | 🖼🧊📄§ | 2026-05-05 | 2042-04-01 | 0 | 31 |
| 12617820 | Engineered coronavirus spike (s) protein and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-05-28 | 0 | 31 |
| 12617828 | Genetically modified immune cell, preparation method therefor, and application | 🖼🧊📄§ | 2026-05-05 | 2040-05-06 | 0 | 31 |
| 12617826 | CLEC2 fusion protein and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-09-29 | 0 | 31 |
| 12617831 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | 🖼🧊📄§ | 2026-05-05 | 2040-02-21 | 0 | 31 |
| 12617836 | Tumor environment specific expression of effector genes | 🖼🧊📄§ | 2026-05-05 | 2042-03-21 | 0 | 31 |
| 12617841 | Nucleic acid antibody constructs for use against respiratory syncytial virus | 🖼🧊📄§ | 2026-05-05 | 2039-01-31 | 0 | 31 |
| 12617843 | Human broadly neutralizing antibodies against the membrane-proximal external region of HIV Env for vaccine design and intervention | 🖼🧊📄§ | 2026-05-05 | 2040-10-14 | 0 | 31 |
| 12617850 | Treatment of PD-L1-positive melanoma using an anti-PD-1 antibody | 🖼🧊📄§ | 2026-05-05 | 2042-03-22 | 0 | 31 |
| 12617849 | Antigen specific CD19-targeted CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2040-04-29 | 0 | 31 |
| 12617851 | TREM2 antibodies and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-05 | 0 | 31 |
| 12617856 | Protease-cleavable substrates and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2045-03-17 | 0 | 31 |
| 12617870 | Methods of reversing ticagrelor activity | 🖼🧊📄§ | 2026-05-05 | 2039-09-20 | 0 | 31 |
| 12617864 | Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-04-12 | 0 | 31 |
| 12617866 | Humanized antibodies to mucin-16 and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2040-05-07 | 0 | 31 |
| 12617773 | Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators | 🖼🧊📄§ | 2026-05-05 | 2041-04-30 | 0 | 31 |
| 12617774 | Substituted indole compounds and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2045-05-30 | 0 | 31 |
| 12617797 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | 🖼🧊📄§ | 2026-05-05 | 2041-05-20 | 0 | 31 |
| 12611408 | Methods for treating nail brittleness, fragility, or pitting | 🖼🧊📄§ | 2026-04-28 | 2039-06-04 | 0 | 31 |
| 12611409 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | 🖼🧊📄§ | 2026-04-28 | 2042-03-15 | 0 | 31 |
| 12611423 | Medical use of tafoxiparin | 🖼🧊📄§ | 2026-04-28 | 2043-05-02 | 0 | 31 |
| 12611433 | Anaerostipes sp B2131 strain and application thereof in inflammatory bowel diseases | 🖼🧊📄§ | 2026-04-28 | 2041-01-08 | 0 | 31 |
| 12612441 | Polypeptide and therapeutic uses thereof | 🖼🧊📄§ | 2026-04-28 | 2040-01-07 | 0 | 31 |
| 12612388 | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | 🖼🧊📄§ | 2026-04-28 | 2041-05-20 | 0 | 31 |
| 12612389 | Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same | 🖼🧊📄§ | 2026-04-28 | 2040-07-14 | 0 | 31 |
| 12612390 | Modulators of methyl modifying enzymes, compositions and uses thereof | 🖼🧊📄§ | 2026-04-28 | 2043-04-28 | 0 | 31 |
| 12612402 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | 🖼🧊📄§ | 2026-04-28 | 2045-01-17 | 0 | 31 |
| 12612407 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | 🖼🧊📄§ | 2026-04-28 | 2040-02-06 | 0 | 31 |
| 12612408 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | 🖼🧊📄§ | 2026-04-28 | 2040-06-28 | 0 | 31 |
| 12612424 | HPK1 inhibitors and uses thereof | 🖼🧊📄§ | 2026-04-28 | 2040-07-03 | 0 | 31 |
| 12612460 | Anti-PD-1 antibodies and fusion proteins | 🖼🧊📄§ | 2026-04-28 | 2044-12-20 | 0 | 31 |
| 12612462 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 | 🖼🧊📄§ | 2026-04-28 | 2043-06-07 | 0 | 31 |
| 12612463 | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors | 🖼🧊📄§ | 2026-04-28 | 2044-01-19 | 0 | 31 |
| 12611456 | Use of thiazole amide compounds for modulating human immune response | 🖼🧊📄§ | 2026-04-28 | 2040-09-16 | 0 | 31 |
| 12611457 | Bispecific antibodies specifically binding to PD1 and LAG3 | 🖼🧊📄§ | 2026-04-28 | 2042-03-07 | 0 | 31 |
| 12611458 | Chimeric receptors and methods of use thereof | 🖼🧊📄§ | 2026-04-28 | 2043-04-14 | 0 | 31 |
| 12611460 | Eyedrop compositions | 🖼🧊📄§ | 2026-04-28 | 2039-09-18 | 0 | 31 |
| 12611461 | Bioorthogonal compositions | 🖼🧊📄§ | 2026-04-28 | 2045-04-16 | 0 | 31 |
| 12611462 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | 🖼🧊📄§ | 2026-04-28 | 2042-07-14 | 0 | 31 |
| 12611379 | Lipid nano drug delivery system targeting brain lesion and preparation method and application thereof | 🖼🧊📄§ | 2026-04-28 | 2040-11-13 | 0 | 31 |